Miltefosine (hexadecylphosphocholine) is an alkylphosphocholine (APC) lipid analog. It was initially developed as an oral antineoplastic agent but was abandoned owing to dose-limiting gastrointestinal toxicity. It was subsequently found to have useful activity at tolerable dosages against a range of microorganisms, including protozoa and fungi. Clinically, its activity against Leishmania species has received the most attention, as it represented the first effective oral agent for that group of organisms. It was first registered for the treatment of (visceral) leishmaniasis in 2002.
|Title of host publication||Kucers the Use of Antibiotics|
|Subtitle of host publication||A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition|
|Editors||M. Lindsay Grayson|
|Place of Publication||Boca Raton FL USA|
|Number of pages||18|
|Publication status||Published - 2 Oct 2017|